TrialNature communications2026

Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial.

Xavier Santamaria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.